The Vision Restoration Challenge That Cochlear Implants Inspired
The cochlear implant's commercial success in restoring functional hearing to profoundly deaf individuals through an implanted electronic device that bypasses the damaged hair cells of the inner ear and directly stimulates the auditory nerve has been the clinical precedent that retinal implant researchers and developers have explicitly cited as the model whose commercial and clinical development trajectory they aim to replicate for vision restoration. The parallel between the two sensory restoration technologies is genuine: both target sensory systems whose peripheral transducers are damaged or absent while the neural pathways and central nervous system processing required for perception remain intact, both require the engineering of an interface between electronic stimulation and biological neural tissue whose spatial resolution and biocompatibility determine the quality of the restored sensation, and both require the combination of implantable electronics with external signal processing devices whose engineering constraints are defined by the power consumption, heat dissipation, and wireless communication requirements of implantable medical devices. The cochlear implant's journey from first human implant in the 1970s to commercial device approval in the 1980s to mainstream clinical adoption across multiple manufacturers in the 2000s provides the forty-year arc whose retinal implant equivalent began with Second Sight Medical Products' Argus II receiving CE Mark in 2011 and FDA approval in 2013.
The retinal implant market's commercial development has proceeded along two distinct anatomical approaches whose differences in implant location, stimulation mechanism, and patient eligibility create different clinical and commercial profiles. Epiretinal implants, whose electrode array is placed on the inner surface of the retina facing the vitreous cavity, stimulate the retinal ganglion cells whose axons form the optic nerve that carries visual information to the brain. Subretinal implants, whose electrode array or photovoltaic pixel array is placed beneath the retina between the photoreceptor layer and the retinal pigment epithelium, stimulate the inner nuclear layer neurons whose preserved function in the retinal degenerative diseases that cause most cases of acquired blindness creates the specific patient population whose residual neural circuitry the subretinal approach can interface with.
Pixium Vision and the PRIMA Photovoltaic Approach
Pixium Vision's PRIMA system is the most clinically advanced subretinal retinal implant and the one whose photovoltaic stimulation mechanism represents the most significant technical departure from the conventional electronic implant approach that Second Sight's Argus II used. Rather than delivering electrical stimulation through an active implant powered by a transcutaneous inductive link, the PRIMA subretinal implant is a passive photovoltaic pixel array that converts near-infrared light projected onto the retina by the patient's custom glasses into the electrical stimulation that activates retinal neurons. The photovoltaic approach eliminates the need for an implantable power receiver and transmission coil, reducing the implant to the pixel array itself whose passive design creates the minimal implant volume and absence of implant heating that the subretinal location's proximity to the fovea requires for safety. Pixium Vision's PRIMA feasibility clinical trial results, published in Nature Biomedical Engineering, demonstrated that patients with geographic atrophy secondary to age-related macular degeneration could read letters and recognise faces with PRIMA stimulation in combination with their residual peripheral vision, creating the clinical evidence that the CE Mark evaluation pathway requires for a medical device whose benefit must be demonstrated in the patient population it is intended to treat.
Second Sight Medical Products' Argus II, the epiretinal implant that held the only regulatory approval for a retinal prosthesis in the United States and Europe for several years, demonstrated both the clinical feasibility and the commercial challenges of retinal implants. Its FDA-approved indication for retinitis pigmentosa patients with bare light perception or less vision provided the regulatory framework for marketing but also constrained the potential patient population to a smaller number than the broader retinal degeneration population that subretinal approaches targeting macular degeneration may eventually serve. Second Sight's subsequent financial difficulties and its pivot to cortical visual prosthesis development through the Orion cortical stimulation device reflect the commercial complexity of a first-generation retinal prosthesis market whose reimbursement coverage, patient selection criteria, and device performance have defined the commercial constraints that second-generation devices must overcome to achieve the commercial scale that the cochlear implant model eventually reached.
The Patient Population and the Reimbursement Pathway
The commercial addressable market for retinal implants depends critically on which retinal diseases the devices can effectively treat and which patient selection criteria define the eligible population within those disease categories. Retinitis pigmentosa, whose hereditary degeneration of rod photoreceptors followed by cone photoreceptors creates the outer retinal cell loss that both epiretinal and subretinal implants target, affects approximately one in four thousand individuals globally, creating a patient population of several million worldwide whose advanced-stage disease, characterised by severe visual loss with preserved inner retinal neurons, defines the implant-eligible subset. Age-related macular degeneration, the more prevalent retinal disease whose geographic atrophy form creates the specific pattern of outer retinal cell loss in the central visual field that PRIMA's subretinal photovoltaic approach targets, affects millions of patients in the advanced disease stage that might be eligible for subretinal implant treatment, creating a substantially larger potential commercial market than retinitis pigmentosa alone if the clinical evidence and regulatory approvals for AMD can be established.
Top 10 Companies in Retinal Implants and Visual Prosthetics Globally
- Second Sight Medical Products: US retinal prosthesis company with the Argus II epiretinal implant, the first FDA-approved retinal prosthesis; its CE Mark and FDA approval history and its pivot to the Orion cortical visual prosthesis create the commercial retinal prosthesis pioneer whose regulatory pathway development and clinical experience inform the entire retinal implant field's commercial development.
- Pixium Vision: French subretinal photovoltaic implant company with the PRIMA system for geographic atrophy; its photovoltaic pixel array that eliminates the external power transmitter and its published clinical trial results demonstrating letter reading with PRIMA stimulation create the most commercially advanced second-generation retinal implant whose CE Mark pathway targets the larger age-related macular degeneration patient population.
- Retina Implant: German subretinal electronic implant company with the Alpha AMS device for retinitis pigmentosa; its subretinal location whose stimulation of preserved inner retinal neurons creates higher spatial resolution potential than epiretinal stimulation and its long-term implant safety data create the German medical technology company's retinal implant commercial position.
- Nano-Retina: Israeli retinal implant company with the Bio-Retina nano-electronic implant for retinitis pigmentosa; its nano-scale photovoltaic pixel array and its minimally invasive implantation approach that uses a syringe-based delivery rather than a formal surgical procedure create the retinal implant commercial position whose procedural simplicity addresses the surgical access barrier that complex retinal implant surgery creates.
- Bionic Vision Technologies: Australian retinal prosthesis company with wide-view and high-acuity epiretinal implants; its Bionic Vision Australia consortium heritage and its wide-angle photovoltaic retinal stimulation technology create the Australian academic-commercial retinal prosthesis development programme whose wide visual field implant addresses the peripheral vision restoration that activities of daily living require beyond the central vision that current implants primarily restore.
- IMI (Institut fuer Mikroelektronik und Mechatronik Systems): German research institute developing high-density retinal implant arrays for improved visual resolution; its microelectronics fabrication capability and its retinal stimulation research create the technology development infrastructure that advances the electrode density and stimulation selectivity that higher-resolution retinal implants require to progress from light and motion perception to functional form vision.
- EpiRet: German epiretinal implant company with wireless epiretinal stimulation system development; its inductive wireless power and data transmission and its epiretinal electrode array create the German academic-industrial retinal implant development partnership whose technical approach to wireless implant communication informs the broader field's device engineering.
- Stanford Photovoltaic Retinal Prosthesis Group: US academic research group developing photovoltaic subretinal implants whose wireless near-infrared stimulation principle underlies the Pixium Vision PRIMA technology; its continued research into higher pixel density photovoltaic arrays and alternative stimulation strategies creates the academic pipeline for the next generation of retinal implant technology beyond current commercial products.
- SightPlus: French startup developing next-generation high-density retinal implants with artificial intelligence image processing; its AI-based image processing that optimises the stimulation pattern for each patient's residual neural circuitry creates the personalised retinal prosthesis approach whose adaptive stimulation may improve perceived image quality beyond what fixed stimulation parameter implants achieve.
- GenSight Biologics: French optogenetics company using gene therapy to restore light sensitivity to remaining retinal cells rather than electronic stimulation; its optogenetics approach that delivers the channelrhodopsin gene to surviving inner retinal cells and activates them with pulsed light from specialised goggles creates the biological rather than electronic retinal prosthetic whose performance in clinical trials has demonstrated navigational light perception in profoundly blind patients.